(CSI) Competitors

RIV Capital (TSE:RIV) and (CSI) (CNSX:CSI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.

Profitability

This table compares RIV Capital and (CSI)'s net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for RIV Capital and (CSI), as reported by MarketBeat.com.

RIV Capital currently has a consensus target price of C$4.00, suggesting a potential upside of 96.08%.

Valuation and Earnings

This table compares RIV Capital and (CSI)'s revenue, earnings per share and valuation.

(CSI) has lower revenue, but higher earnings than RIV Capital.

Summary

RIV Capital beats (CSI) on 1 of the 1 factors compared between the two stocks.

Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) and (CSI) (CNSX:CSI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Willow Biosciences Inc. (WLLW.TO) and (CSI)'s top-line revenue, earnings per share (EPS) and valuation.

(CSI) has lower revenue, but higher earnings than Willow Biosciences Inc. (WLLW.TO).

Profitability

This table compares Willow Biosciences Inc. (WLLW.TO) and (CSI)'s net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for Willow Biosciences Inc. (WLLW.TO) and (CSI), as provided by MarketBeat.com.

Willow Biosciences Inc. (WLLW.TO) currently has a consensus price target of C$2.25, suggesting a potential upside of 75.78%.

Summary

Willow Biosciences Inc. (WLLW.TO) beats (CSI) on 1 of the 1 factors compared between the two stocks.

(CSI) (CNSX:CSI) and MediPharm Labs (TSE:LABS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares (CSI) and MediPharm Labs' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares (CSI) and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

(CSI) has higher earnings, but lower revenue than MediPharm Labs.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for (CSI) and MediPharm Labs, as provided by MarketBeat.com.

MediPharm Labs has a consensus price target of C$1.53, suggesting a potential upside of 229.03%.

Summary

MediPharm Labs beats (CSI) on 2 of the 2 factors compared between the two stocks.

(CSI) (CNSX:CSI) and Khiron Life Sciences (CVE:KHRN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares (CSI) and Khiron Life Sciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares (CSI) and Khiron Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

(CSI) has higher earnings, but lower revenue than Khiron Life Sciences.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for (CSI) and Khiron Life Sciences, as provided by MarketBeat.com.

Khiron Life Sciences has a consensus price target of C$1.20, suggesting a potential upside of 135.29%.

Summary

Khiron Life Sciences beats (CSI) on 1 of the 1 factors compared between the two stocks.

(CSI) (CNSX:CSI) and Delta 9 Cannabis (TSE:DN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares (CSI) and Delta 9 Cannabis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for (CSI) and Delta 9 Cannabis, as provided by MarketBeat.

Delta 9 Cannabis has a consensus target price of C$1.10, suggesting a potential upside of 89.66%.

Valuation & Earnings

This table compares (CSI) and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

(CSI) has higher earnings, but lower revenue than Delta 9 Cannabis.

Summary

Delta 9 Cannabis beats (CSI) on 2 of the 2 factors compared between the two stocks.

Meta Growth (CVE:META) and (CSI) (CNSX:CSI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares Meta Growth and (CSI)'s gross revenue, earnings per share (EPS) and valuation.

(CSI) has lower revenue, but higher earnings than Meta Growth.

Profitability

This table compares Meta Growth and (CSI)'s net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Meta Growth and (CSI), as reported by MarketBeat.

Summary

Meta Growth beats (CSI) on 1 of the 1 factors compared between the two stocks.